MarketCap
Teleflex Incorporated TFX
$ 137.03
0.61%
Facebook
X
Telegram
Teleflex Incorporated Operating Income | TFX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Teleflex Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.9 M | 52.4 M | 259 M | 500 M | 628 M | 423 M | 427 M | 322 M | 372 M | 319 M | 316 M | 285 M | 233 M | -97.4 M | 230 M | 230 M | 250 M | 226 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 628 M | -97.4 M | 277 M |
Quarterly Operating Income Teleflex Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.8 M | 20.2 M | -409 M | 155 M | 126 M | 149 M | 117 M | -4.79 M | 165 M | 144 M | 115 M | - | 132 M | 135 M | 104 M | - | 241 M | 129 M | 103 M | 95.1 M | 132 M | 38.8 M | 157 M | 127 M | 118 M | 107 M | 75.2 M | 119 M | 82.1 M | 33.5 M | 86.8 M | 90.9 M | 110 M | 110 M | 60.8 M | 67 M | 86.5 M | 98.4 M | 67.5 M | 96.7 M | 76.6 M | 77 M | 65.6 M | 69.2 M | 81.9 M | 74.8 M | 59 M | 54.1 M | 66 M | 63.8 M | 49.4 M | 58.4 M | 49.8 M | 64.7 M | -270 M | 63.1 M | 61.9 M | 55.9 M | 48.7 M | 67.7 M | 79.4 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 241 M | -409 M | 75.8 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
-16.6 M | $ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Harvard Bioscience
HBIO
|
-48.6 M | $ 8.32 | 1.09 % | $ 369 M | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 165.91 | -0.46 % | $ 4.09 B | USA |
 |
InfuSystem Holdings
INFU
|
11.9 M | $ 13.8 | -1.0 % | $ 285 M | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 121.86 | 0.49 % | $ 3.9 B | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 451.72 | -0.13 % | $ 161 B | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 84.26 | -0.22 % | $ 1.91 B | USA |
 |
Nephros
NEPH
|
1.15 M | $ 3.6 | 1.98 % | $ 38.2 M | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 23.68 | 0.32 % | $ 3.98 B | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 4.17 | 0.97 % | $ 306 M | USA |
 |
Pro-Dex
PDEX
|
13 M | $ 61.53 | -1.11 % | $ 198 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 52.77 | -0.47 % | $ 3.56 B | USA |
 |
Repligen Corporation
RGEN
|
55.2 M | $ 180.01 | 1.74 % | $ 10.1 M | USA |
 |
ResMed
RMD
|
1.89 B | $ 253.31 | 0.18 % | $ 36.9 B | USA |
 |
Retractable Technologies
RVP
|
-21.2 M | $ 0.58 | -0.02 % | $ 17.4 M | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 23.16 | 2.43 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
1.1 B | $ 229.89 | -0.97 % | $ 22.6 B | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 0.99 | -2.99 % | $ 90 M | USA |
 |
Utah Medical Products
UTMD
|
11.4 M | $ 73.36 | -1.17 % | $ 238 M | USA |
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M | USA |
 |
West Pharmaceutical Services
WST
|
585 M | $ 395.17 | 0.77 % | $ 28.6 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 9.22 | -2.28 % | $ 1.84 B | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
-39.9 M | $ 12.17 | -1.62 % | $ 505 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 195.87 | -1.37 % | $ 56.3 B | USA |
 |
The Cooper Companies
COO
|
683 M | $ 61.11 | -0.16 % | $ 12.2 B | USA |
 |
electroCore
ECOR
|
-13.2 M | $ 7.51 | 6.52 % | $ 63.7 K | USA |
 |
Glaukos Corporation
GKOS
|
-200 M | $ 178.61 | -0.15 % | $ 10.2 B | USA |
 |
Haemonetics Corporation
HAE
|
157 M | $ 119.33 | 0.69 % | $ 5.63 B | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 3.13 | -1.26 % | $ 145 M | USA |
 |
Milestone Scientific
MLSS
|
-5.7 M | $ 0.31 | 1.02 % | $ 25.4 M | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 94.16 | 0.92 % | $ 5.57 B | USA |
 |
Alcon
ALC
|
1.36 B | $ 70.0 | -0.24 % | $ 34.5 B |  Schweiz |
 |
AtriCure
ATRC
|
-9.45 M | $ 61.13 | 3.66 % | $ 2.92 B | USA |
 |
Baxter International
BAX
|
-308 M | $ 25.28 | -0.08 % | $ 13 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 0.95 | -2.44 % | $ 43.5 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
-37.5 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
-114 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
-267 M | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |